Verrica Pharmaceuticals Inc (VRCA) Stock Price, Quote & News

Company Profile

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 453 3300

Website: www.verrica.com

Address:

44 West Gay Street, Suite 400, West Chester, United States

Merlintrader Apr. 13 at 3:36 PM

$VRCA

0 · Reply

Merlintrader Apr. 10 at 1:34 PM

$VRCA Verrica Pharmaceuticals ( $VRCA): deep dive 2026 after the balance-sheet reset, the YCANTH ramp and the renewed VP-315 scientific story https://www.merlintrader.com/verrica-pharmaceuticals-deepdive-april2026/

0 · Reply

focafoca99 Apr. 9 at 9:11 PM

$VRCA said a late-breaking abstract on VP-315 was accepted for SID 2026, with the company highlighting a potential abscopal effect in basal cell carcinoma.

0 · Reply

SuperGreenToday Apr. 9 at 2:52 AM

$VRCA

0 · Reply

focafoca99 Apr. 6 at 6:31 PM

$VRCA is just promoting participation in the Needham healthcare conference.

0 · Reply

JeanPaules Mar. 30 at 6:08 PM

$VRCA

0 · Reply

BioGem Mar. 14 at 11:53 PM

$VRCA Shortable above 6$. Including the additional vested pre-funded warrants, they have near 21.5M shares outstanding, and the mkt cap of 130M. Too expensive with many critical negatives: -No growth QOQ of product revenue. Means adoption is poor. Generics and new at-home options are ruthless competition. -Deep operating and bottom-line losses to deepen through 2026 (expansion of sales and marketing and launching new trials). -Much lower accounts receivable and higher current liabilities now, mean a big cash burn in Q1 26. -Cash will run out before year end = Another very dilutive offering will be required.

1 · Reply

prismmarketview Mar. 12 at 1:33 PM

We've added Verrica Pharmaceuticals (NASDAQ: $VRCA) to the PRISM Pharmaceuticals Index, spotlighting its focused work in dermatology and specialty care. YCANTH is gaining solid early commercial traction, with strong 2025 revenue growth reflecting increasing adoption for molluscum contagiosum. The pipeline continues to advance meaningfully: a global Phase 3 program for common warts is underway following the first patient dosing late last year, and VP-315 is progressing in development as a potential non-surgical option for basal cell carcinoma. This addition underscores Verrica's commitment to addressing unmet needs in skin disease treatments. @VerricaPharma #Pharmaceuticals https://prismmarketview.com/companies/verrica-pharmaceuticals-inc/

0 · Reply

mikesterz7 Mar. 11 at 12:50 PM

$VRCA Brookline Capital Acquisition upgraded shares of Verrica Pharmaceuticals from a "hold" rating to a "buy" rating and set a $17.00 target price.

0 · Reply

OpenOutcrier Mar. 11 at 12:49 PM

$VRCA (-10.0% pre) VRCA: Revenue growth and cost controls narrowed losses, but liquidity risks persist https://ooc.bz/l/96291

0 · Reply

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Apr 6, 2026, 8:00 AM EDT - 8 days ago

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

Mar 20, 2026, 7:42 PM EDT - 24 days ago

VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm

Mar 20, 2026, 9:09 AM EDT - 25 days ago

VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA

Mar 19, 2026, 2:15 PM EDT - 26 days ago

Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA

Mar 11, 2026, 8:00 AM EDT - 4 weeks ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 5, 2026, 8:00 AM EST - 5 weeks ago

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

Feb 23, 2026, 8:00 AM EST - 7 weeks ago

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 12, 2026, 8:00 AM EST - 2 months ago

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

Feb 9, 2026, 8:00 AM EST - 2 months ago

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

Jan 7, 2026, 8:00 AM EST - 3 months ago

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Nov 24, 2025, 8:00 AM EST - 5 months ago

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

Nov 14, 2025, 4:05 PM EST - 5 months ago

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 5 months ago

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

Oct 24, 2025, 11:00 AM EDT - 6 months ago

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 20, 2025, 4:05 PM EDT - 6 months ago

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

Oct 7, 2025, 4:05 PM EDT - 6 months ago

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 19, 2025, 8:00 AM EDT - 7 months ago

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

Sep 2, 2025, 7:00 AM EDT - 8 months ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:01 PM EDT - 8 months ago

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 8 months ago

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

Jul 9, 2025, 7:00 AM EDT - 9 months ago

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

Jul 1, 2025, 7:00 AM EDT - 10 months ago

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

May 28, 2025, 8:00 AM EDT - 11 months ago

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 13, 2025, 4:05 PM EDT - 11 months ago

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 7, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 7:00 AM EST - 1 year ago

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

Feb 25, 2025, 4:05 PM EST - 1 year ago

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

Dec 9, 2024, 4:15 PM EST - 1 year ago

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 6, 2024, 8:00 AM EST - 1 year ago

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Nov 21, 2024, 7:30 AM EST - 1 year ago

Verrica Announces Pricing of $42.0 Million Public Offering

Nov 20, 2024, 4:05 PM EST - 1 year ago

Verrica Announces Proposed Public Offering

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

Oct 11, 2024, 5:21 PM EDT - 1 year ago

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

Sep 27, 2024, 10:29 PM EDT - 1 year ago

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

Aug 14, 2024, 7:45 AM EDT - 1 year ago

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

Jul 1, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

May 15, 2024, 7:30 AM EDT - 2 years ago

Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

May 13, 2024, 7:30 AM EDT - 2 years ago

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

May 9, 2024, 7:30 AM EDT - 2 years ago

Verrica Pharmaceuticals to Present at Upcoming Investor Conferences

Merlintrader Apr. 13 at 3:36 PM

$VRCA

0 · Reply

Merlintrader Apr. 10 at 1:34 PM

0 · Reply

focafoca99 Apr. 9 at 9:11 PM

$VRCA said a late-breaking abstract on VP-315 was accepted for SID 2026, with the company highlighting a potential abscopal effect in basal cell carcinoma.

0 · Reply

SuperGreenToday Apr. 9 at 2:52 AM

$VRCA

0 · Reply

focafoca99 Apr. 6 at 6:31 PM

$VRCA is just promoting participation in the Needham healthcare conference.

0 · Reply

JeanPaules Mar. 30 at 6:08 PM

$VRCA

0 · Reply

BioGem Mar. 14 at 11:53 PM

1 · Reply

prismmarketview Mar. 12 at 1:33 PM

0 · Reply

mikesterz7 Mar. 11 at 12:50 PM

$VRCA Brookline Capital Acquisition upgraded shares of Verrica Pharmaceuticals from a "hold" rating to a "buy" rating and set a $17.00 target price.

0 · Reply

OpenOutcrier Mar. 11 at 12:49 PM

$VRCA (-10.0% pre) VRCA: Revenue growth and cost controls narrowed losses, but liquidity risks persist https://ooc.bz/l/96291

0 · Reply

StocktwitsEarnings Mar. 11 at 12:15 PM

$VRCA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.57 up 76.35% YoY • Reported revenue of $5.09M up 1380.23% YoY • Verrica Pharmaceuticals Inc. believes its $30.1M cash as of December 31, 2025, is sufficient until Q1 2027, but substantial doubt exists about its ability to continue as a going concern for one year without additional funding.

0 · Reply

ash1012 Mar. 9 at 2:04 PM

$VRCA get in now going to double this week

0 · Reply

OfficialStocktwitsUser Mar. 3 at 4:18 AM

$VRCA RSI: 27.22, MACD: -0.4845 Vol: 0.70, MA20: 6.11, MA50: 7.17 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ash1012 Mar. 2 at 3:52 PM

$VRCA WILL GO PARABOLIC ON MARCH 10TH, START LOADING

1 · Reply

BillionerOfKing Feb. 21 at 5:15 PM

$VRCA Current Stock Price: $5.78

0 · Reply

BillionerOfKing Feb. 12 at 11:46 PM

$VRCA Current Stock Price: $5.57 Contracts to trade: $2.5 VRCA Feb 20 2026 Call Entry: $0.05 Exit: $0.06 ROI: 29% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SnipeEdge Feb. 10 at 12:58 PM

$VRCA is a biotech (Verrica Pharmaceuticals) with a dermatology treatment; commercial launch execution is critical.

0 · Reply

invisiblehand21 Feb. 3 at 9:29 PM

$VRCA hoping the iv isn't lying

0 · Reply

invisiblehand21 Feb. 3 at 8:34 PM

$VRCA i see iv 400 on good news, i buy

0 · Reply

Paper_Route_Frank Jan. 17 at 1:21 PM

$VRCA avg 9.50

0 · Reply

Market Cap	87.79M
Revenue (ttm)	35.58M
Net Income (ttm)	-17.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-50.28%
Debt to Equity Ratio	0.00

Volume	103,298
Avg Vol	130,910
Day's Range	N/A - N/A
Shares Out	17.18M
Stochastic %K	67%
Beta	1.42
Analysts	Sell
Price Target	$16.50